Targeting the Inactive Conformation of the Epidermal Growth Factor Receptor Identifies EG31: A Novel Small Molecule Inhibitor Effective Against Normal and 5-Fluorouracil-Resistant Triple Negative Breast Cancer Cells
This study identified EG31 targeting the inactive conformation of EGFR, offering a promising therapeutic approach to overcome 5-FU resistance in TNBC. Further research could enhance treatment efficacy and provide a new avenue for managing this challenging cancer subtype.
Authors
- Hassan M. Otifi (ORCID: https://orcid.org/0000-0002-1735-6041)
Institutions
- King Khalid University (SA)
Publication Details
- Journal
- OncoTargets and Therapy
- Published
- 2025-05-01
- DOI
- https://doi.org/10.2147/ott.s512184
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05